Fig. 2

IL-22 deficiency leads to improved clinical signs of neurological disease in ZIKV-infected neonatal mice. Neonatal WT and IL-22^-/- mice were s.c. infected with ZIKV. a Body weight, b survival rates, c paralysis rates, and d clinical signs of neurological disease were recorded. e Neonatal WT mice were s.c. infected with ZIKV, followed by rIL-22 treatment (1 μg in 5 μL, s.c.) every other day. Uninfected mice were used as controls. Bodyweights were monitored and statistical analyses were performed between PBS and rIL-22 groups of infected mice (8–10 mice/group) f Paralysis rates were generated by pooling the data of three independent experiments (7–9 mice/group). A two-tailed Student’s t test was used to compare the two groups. One-way ANOVA was used to compare more than two groups. Log-rank (Mantel-Cox) test was used for survival curve analysis. *p < 0.05, **p < 0.01, and ***p < 0.001